BMS-986165 + cyclosporine

BMS-986165 + cyclosporine is an investigational combination of two drugs:

• BMS-986165 (deucravacitinib) is a selective oral inhibitor of tyrosine kinase 2 (TYK2), developed by Bristol Myers Squibb. It modulates immune signaling pathways involved in inflammatory and autoimmune diseases, such as psoriasis and psoriatic arthritis.
• Cyclosporine is a calcineurin inhibitor immunosuppressant that inhibits T-cell activation by blocking interleukin-2 transcription. It has been used for decades to treat conditions like severe psoriasis and organ transplant rejection.

The combination has been studied in healthy subjects to assess pharmacokinetics, safety, and tolerability; results indicate it was well tolerated with no clinically meaningful drug-drug interaction. There are no approved indications for the combination; both drugs are individually approved or under investigation for various immune-mediated diseases.